NEW YORK, March 26 - Affymetrix and Oxford Gene Technology said Monday they had settled a multinational patent infringement dispute, allowing both companies to proceed in licensing and developing their microarray technology.

The companies, which have been entrenched in a legal battle since 1999, would not disclose the terms of the settlement, but Affymetrix said that it would incure a $19 million charge as well as other possible legal fees.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.